AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports

· cnbc.com

U.K. pharmaceutical giant AstraZeneca is considering a deal to merge with its U.S. rival Bristol Myers Squibb.

A smart acquisition strategy has made Bristol-Meyers, which has bought seven companies since October 2007, a big player in the cancer-treatment industry. Its pu...


Read on WOBR AI → · More AI market news · StrategyVerse · Quant Research · WOBR.AI